Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Terminated × Glioblastoma × Clear all

Phase

Phase 2 71 Phase 1 62 Phase 1/2 25 Phase NA 12 Phase EARLY_PHASE1 10 Phase 3 6 Phase 4 1 Phase 2/3 1

Status

Unknown 4 Recruiting 3 Active not recruiting 3 Withdrawn 2 Terminated 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 10 Carcinoma, Non-Small-Cell Lung 10 Breast Neoplasms 10 Lung Neoplasms 8 Prostatic Neoplasms 6 Recurrence 5 Neoplasm Metastasis 5 Stomach Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Pancreatic Neoplasms 4 Multiple Myeloma 4 Head and Neck Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Ovarian Neoplasms 3 Myelodysplastic Syndromes 3 Melanoma 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Large B-Cell, Diffuse 3 Liver Neoplasms 3 Hematologic Neoplasms 3 Fatigue 3 Esophageal Neoplasms 3 Depression 3 Carcinoma, Squamous Cell 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Rectal Neoplasms 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Parasomnias 2

Interventions

vocimagene amiretrorepvec 1 Temozolomide 1 Lomustine 1 Flucytosine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡